Cilengitide Merck

Curr Opin Investig Drugs. 2003 Jun;4(6):741-5.


Merck KGaA is developing cilengitide, the lead in a series of integrin antagonists with anti-angiogenic activities, for the potential treatment of a variety of cancer types. The National Cancer Institute is conducting clinical trials of cilengitide. In October 1999, phase II trials in non-small-cell lung cancer (as a monotherapy) and pancreatic cancer (in combination with gemcitabine) were initiated. These were ongoing in February 2002, by which time, a phase I trial and a phase I/II trial in glioblastoma were underway.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / chemical synthesis
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Clinical Trials as Topic / statistics & numerical data
  • Drugs, Investigational / therapeutic use
  • Humans
  • Neoplasms / drug therapy
  • Snake Venoms / chemical synthesis
  • Snake Venoms / therapeutic use*
  • Technology, Pharmaceutical / methods*


  • Angiogenesis Inhibitors
  • Drugs, Investigational
  • Snake Venoms
  • Cilengitide